

# Index

- Aβ. *See* β-amyloid (Aβ); cerebral amyloid angiopathy (CAA)
- α-dystroglycan, 103, 106
- αβ-galactosidase deficiency, 293–294,  
*See also* Fabry's disease
- ABri precursor protein (ABriPP)-related cerebral amyloid angiopathy, 86–88
- acute small deep infarcts (ASDI), 129–132
- acute stroke care, 323–325  
 anticoagulation, 228  
 antiplatelet therapy, 227–228, 325  
 blood pressure management, 227  
 intra-arterial stenting, 228–229  
 stroke unit care, 229  
 thrombolytic therapy, 226–227, 323–324
- adhesion molecules, 193–194
- age-related changes  
 blood–brain barrier, 54  
 large artery aging related to white matter pathology, 93
- Aicardi–Goutières syndrome (AGS), 69, 86
- albumin, blood–brain barrier evaluation, 54
- Alzheimer's disease (AD), 29,  
*See also* dementia
- anti-Aβ immunotherapy, 73
- cerebral amyloid angiopathy association, 8–13, 200, 205–206
- cerebral blood flow studies, 184
- cerebral microbleeds, 35–36, 237, 302  
 cognitive significance, 238
- diagnosis, 298
- familial (FAD), 205
- mixed dementia, 299
- small vessel–disease interaction, 300–302  
 challenges, 304–305  
 mechanisms, 304
- vascular cognitive impairment relationship, 16
- vascular dementia pathology relationship, 200, 302–304
- white matter changes, 301–302
- nonfocal white matter disease, 20
- American Heart Association/  
 American Stroke Association (AHA/ASA) guidance, 349–350
- amyloid disease, animal models, 45,  
*See also* β-amyloid (Aβ); cerebral amyloid angiopathy (CAA)
- amyloid precursor protein (APP), 70,  
*See also* β-amyloid (Aβ)  
 APP metabolism biomarkers, 207  
 APP metabolism disturbance, 207  
 APP-related cerebral amyloid angiopathy, 86  
 mutations, 71, 86
- amyloid-specific molecular imaging, 159–160
- angiotensin II (ANGII), 95, 194
- angiotensin receptor (AGTR) genes, 88
- angiotensin-converting enzyme (ACE) gene polymorphisms, 88, 194
- angiotensinogen gene (AGT), 195  
 M235T variant, 88
- animal models, 42, 46–48  
 β-amyloid deposition, 71–72  
 blood–brain barrier, 54–56  
 COL4A1/COL4A2 mutations, 75  
 comorbidities, 45–46  
 advanced age, 45  
 amyloid disease, 45  
 diabetes mellitus, 45–46
- embolic models, 43
- hypertensive models, 44  
 primates, 44  
 stroke-prone spontaneously hypertensive rats (SHRSP), 44
- hypoperfusion-based models, 43  
 acute global ischemic challenge, 43  
 chronic carotid stenosis, 43  
 chronic hypoperfusion, 43  
 focal hypoperfusion, 43  
 mouse unilateral common carotid occlusion (UCCAo), 43
- intervention studies, 46
- utility, 46–47
- vessel damage-based models, 44–45
- CADASIL–Notch3 transgenic mice, 44–45, 66
- hyperhomocysteinemic rodents, 44
- M5R<sup>−/−</sup> transgenic mice, 45
- anterior cerebral artery (ACA), 220
- anterior choroidal artery, 220
- anterior inferior cerebellar artery, 220
- anticoagulation, 228  
 atrial fibrillation and, 330  
 intracerebral hemorrhage association, 33
- antioxidants, 195–196
- antiplatelet therapy, 227–228, 324–325  
 secondary stroke prevention, 325–328
- anxiety, 266–267
- apathy, 263, 267–268  
 prevalence in brain disorders, 267
- APOE ε2 allele, 32–33
- APOE ε4 allele, 32, 35, 206, 318
- apoptosis, 60
- arterial pulsatility, 60
- arterial spin labeling (ASL), 174–176, 182  
 continuous (CASL), 174  
 pseudo-continuous (pCASL), 174  
 pulsed (PASL), 174
- arterial stiffness, 315
- arterial system. *See also specific arteries*  
 heterogeneity, 92–93  
 large artery aging related to microvascular brain damage, 93
- arteriolosclerosis, 56, 348
- arteriosclerotic dementia, 16
- aspirin, 36, 227–228, 325  
 secondary stroke prevention, 325, 328
- astrocytes, 103–104  
 focal ischemia effects, 105, 107
- astroglial reactivity, 202–203
- asymmetric dimethylarginine (ADMA), 194
- CADASIL patients, 197
- ataxic hemiparesis, 221
- atherosclerosis, 6–7, 348  
 common soil hypothesis, 93–95

## Index

- atorvastatin, 328  
 atrial fibrillation, 330  
 atrophy, 351  
   diagnostic significance, 299, 302–303  
 Axenfeld–Rieger anomaly, 85  
 axonal degeneration biomarkers, 207–209
- $\beta$ -amyloid ( $A\beta$ ), 95  
   aggregation, 71  
   anti- $A\beta$  immunotherapy, 73  
   blood–brain barrier dysfunction and, 206  
   clearance pathways, 206  
   diagnostic significance, 303  
   CSF levels, 206–207, 303  
   inflammatory response, 12–13  
   matrix metalloproteinase activation, 32  
   molecular in vivo imaging, 159–160  
   pathological effects, 72–73  
   synthesis and clearance, 71  
   transport across blood–brain barrier, 206  
   vascular deposition, 8–10, 71–72, 205, 304, *See also* cerebral amyloid angiopathy (CAA)  
   cerebral microbleed association, 35  
   topographic distribution, 153
- $\beta$ -catenin, 102  
 balance disorders, 251  
   classification, 251–253  
   LADIS study, 253–254  
   management, 257–258  
   pathological mechanisms, 256–257  
   role in impaired mobility, 255  
   white matter lesion association, 255–256
- basal ganglia, dilation of perivascular spaces, 8  
 basement membrane, 73  
 Benedikt's syndrome, 222  
 Binswanger's encephalopathy, 8, 117  
   cerebral blood flow study, 184  
 biomarkers, 201,  
   *See also* cerebrospinal fluid (CSF)
- bipolar disorder, 265–266  
 bleeding globes, 5  
   microaneurysm rupture, 5  
 blood pressure. *See also* hypertension  
   CADASIL interaction, 287  
   cerebral microbleed relationships, 318–319  
   management, 227, 343  
   secondary stroke prevention, 328–330
- white matter pathology  
   relationships, 315–316  
 blood–brain barrier (BBB), 53–59, 201  
   age-related changes, 54  
   animal models, 54–56  
   dysfunction, 201–202  
    $\beta$ -amyloid as mediator, 206  
   matrix metalloproteinases as biomarkers, 204  
   human clinical data, 57–59  
   management implications, 59  
   human pathological data, 56–57  
   normal findings, 53–54  
   permeability imaging, 58–59
- brain blood vessels. *See also* cerebral microvasculature; *specific vessels*  
   anatomy, 347–348  
   pathology, 348–349  
 brainstem syndromes, 222–224  
*BRI2* gene mutations, 70, 86
- CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy), 33–34, 64–66, 82–84, 283–290  
   clinical manifestations, 64, 82, 284–287, 294  
   cognitive impairment, 286  
   ischemic events, 284  
   migraine, 284–286  
   psychiatric symptoms, 286  
   visual symptoms, 287  
   diagnosis, 289  
   pregenetic screening, 289  
   disease progression, 287–288  
   hemodynamic studies, 188–189  
   imaging findings, 284, 288–289  
   diffusion tensor imaging, 170–171  
   magnetic resonance spectroscopy (MRS), 172–173  
   mechanisms of disease, 65–66  
   brain lesions, 66  
   endothelial dysfunction, 197–198  
   molecular genetics, 65, 84  
   pathology, 64–65, 283–284  
   phenotypic variation, 192, 287  
   prevalence, 82, 283  
   transgenic mouse models, 44–45, 66  
   treatment, 84, 289  
   calcifications, 149  
   candidate gene studies, 88  
   capillary cerebral amyloid angiopathy (capCAA), 9–10  
   capsular infarct, 6
- capsular warning syndrome, 226, 324  
 antiplatelet therapy, 228, 324  
 thrombolytic therapy, 227  
 CARASIL (cerebral autosomal recessive arteriopathy with subcortical ischemic strokes and leukoencephalopathy), 66–68, 84, 290  
   clinical manifestations, 290, 294  
   mechanisms of disease, 68  
   molecular genetics, 67, 290  
   neuroimaging, 290  
   neuropathology, 290
- cardiac arrest, 23  
 encephalopathy, 23  
 carotid endarterectomy (CEA), 330  
 carotid stenosis, 330  
 cavernous malformations, 148–149  
 cerebral amyloid angiopathy (CAA), 8–13, 152–157, 200,  
   *See also*  $\beta$ -amyloid ( $A\beta$ )  
   Alzheimer's disease association, 8–13, 200, 205–206  
   anti- $A\beta$  immunotherapy, 73  
   capillary CAA (capCAA), 9–10  
   cerebral microbleed association, 11, 35–36, 153–154  
   diagnosis, 156–158  
   grading system, 10  
   hereditary CAA, 69–73, 86–88, 159  
   ABri precursor protein-related, 86–88  
   amyloid precursor protein (APP)-related, 86  
   cystatin C-related, 86  
   molecular genetics, 70  
   imaging findings, 152–157  
   arterial spin labeling (ASL), 176  
   molecular in vivo imaging, 159–160  
   intracerebral hemorrhage association, 10–11, 31–33, 153, 158, 317  
   anticoagulation and, 33  
   hypertension and, 32  
   thrombolysis and, 33  
   pathology, 9, 13, 69–70, 205  
    $\beta$ -amyloid aggregation, 71  
    $\beta$ -amyloid deposition, 8–10, 71–72  
   brain lesion mechanisms, 72–73  
   cerebral white matter damage, 12, 155  
   inflammatory changes, 12–13, 156–157  
   microinfarcts, 12  
   subarachnoid hemorrhage association, 33, 152, 155

## Index

- superficial siderosis association, 11, 34, 152, 155
- cerebral arteries, 347
- anterior cerebral artery (ACA), 220
- microangioarchitectural changes, 7
- middle cerebral artery (MCA)
- flow velocity measurement, 182
- posterior cerebral artery (PCA), 220
- cerebral autoregulation, 183
- imaging studies in small vessel diseases, 188
- cerebral blood flow (CBF), 180
- arterial spin labeling studies, 174–176
- autoregulation, 183
- imaging studies, 188
- CADASIL relationship, 188–189
- in small vessel diseases, 183–187
- large artery aging relationships, 93
- local regulation, 105
- measurement, 180–183
- contrast CT perfusion, 182
- magnetic resonance perfusion, 182
- nuclear medicine methods, 180–182
- transcranial Doppler ultrasound (TCD), 182
- volume flow methods, 182
- regional variation, 100
- cerebral hemorrhage. *See* intracerebral hemorrhage (ICH)
- cerebral microbleeds (CMB), 11, 34–37, 300, 304, 317–319
- Alzheimer's disease association, 35–36, 237–238, 302
- as surrogate markers, 340–342
- cerebral microangiopathy association, 342
- clinical outcome correlation, 342
- cerebral amyloid angiopathy
- association, 11, 35–36, 153–154
- cognitive implications, 237–238
- definition, 143–144
- differential diagnosis, 147–150
- calcifications, 149
- causes other than cerebral small vessel disease, 149–150
- cavernous malformations, 148–149
- cerebral metastases from malignant melanoma, 149
- vascular flow voids, 147–148
- epidemiology, 34, 147
- incidence, 342
- imaging findings, 142–150
- blooming effect, 143–145
- echo time significance, 145
- magnetic field strength role, 145
- neuropathological correlates, 34–35
- spatial resolution, 145
- susceptibility-weighted imaging (SWI), 145–147
- intracerebral hemorrhage
- relationships, 36
- mimics, 143, 147
- pathogenesis, 35–36
- prognostic significance, 278–279
- research definition, 351
- risk factors, 318–319
- topographical distribution, 35
- vessel wall thickness relationship, 36
- warfarin association, 33
- cerebral microvasculature, 99–105
- collateral system and protection, 100–101
- elements of, 101–104
- astrocytes, 103
- endothelium, 101–103
- extracellular matrix (ECM), 103, 106
- mast cells, 104
- microglia, 104
- pericytes, 103–104
- focal ischemia effects, 105–107
- clinically relevant microvessel effects, 107–109
- edema, 107
- focal no-reflow, 108–109
- hemorrhagic transformation, 107–108
- matrix adhesion, 106
- microvessel–neuron
- relationships, 106–107
- permeability barrier, 107
- ultrastructural changes, 105–106
- microvessel beds, 100
- neuron relationships, 101, 106
- focal ischemia effects, 106–107
- vessel–neuron communication, 105
- permeability barrier, 99, 104–105, 107
- cerebral reactivity, 183
- hypertension relationship, 175–176
- imaging studies in small vessel diseases, 187–188
- measurement, 183
- white matter pathology association, 315
- cerebral small vessel diseases (SVDs), 1, 4
- Alzheimer's disease interaction, 300–302, 304
- challenges, 304–305
- assessment, 23–26
- balance disorder association, 255–256
- complexity, 218–219
- lesion location, 219
- stroke mechanism, 218–219
- consequences, 273
- definition, 1–2
- new developments, 317
- dementia relationship, 25–26
- etiologic classification, 2
- falls and, 256
- future directions, 349–351
- hemorrhagic, 29, 139,
- See also* cerebral microbleeds (CMB); intracerebral hemorrhage (ICH)
- hereditary conditions, 64,
- See also specific conditions*
- imaging findings, 117
- computed tomography (CT), 118–121
- magnetic resonance imaging (MRI), 118–125
- ischemic consequences, 16–17
- neurovascular unit and, 109–111
- nosological issues, 1–2
- pathogenic mechanisms, 52, 59, 349
- apoptosis, 60
- blood–brain barrier, 53–59
- increased arterial pulsatility, 60
- ischemia, 52–53
- venous pathology, 59–60
- prevalence, 29
- research definitions, 351
- subtypes, 2
- cerebroretinal vasculopathy (CRV), 68, 85, 292
- cerebrospinal fluid (CSF), 200–201
- biomarkers, 201, 209
- amyloid precursor protein metabolism, 207
- axonal degeneration, 207–209
- blood–brain barrier dysfunction, 201–202
- glial involvement, 202–204
- inflammation, 204–205
- cerebrovascular disease (CVD)–
- cognition relationships, 24
- Charcôt–Bouchard aneurysm, 4
- cholesterol. *See also* statin therapy
- cerebral microbleed relationship, 318
- secondary stroke prevention, 328
- white matter pathology
- relationships, 315–316
- circle of Willis, 100
- circulating progenitor cells (CPC)
- CADASIL patients, 197
- Claude's syndrome, 222

## Index

- clopidogrel, 228, 325  
 secondary stroke prevention, 325, 328
- cognitive function. *See also* dementia  
 assessment, 239  
 attention, slowing and motor skills, 241–242  
 executive function, 240–241  
 global measures, 239–240  
 CADASIL patients, 286  
 magnetic resonance spectroscopy (MRS) studies, 173  
 microstructural brain tissue change impact, 342–343  
 small vessel disease impact, 236  
 cerebral microbleeds, 237–238  
 lacunes, 237, 339, 341  
 white matter changes, 236–237, 337, 340
- COL4A1 mutations, 74, 85, 94, 290–292  
 clinical manifestations, 290–291, 294  
 genetics, 291–292  
 imaging findings, 291  
 modifiers of disease phenotype, 76  
 mouse models, 75  
 pathogenicity, 75–76  
 pathologic effects, 73–74, 85, 159  
 porencephalic phenotype, 291
- COL4A2 mutations, 74  
 modifiers of disease phenotype, 76  
 mouse models, 75  
 pathogenicity, 75–76  
 pathologic effects, 73–74
- collagen. *See* type IV collagen
- collateral system, 100–101
- common soil hypothesis, 93–95
- corpus striatum, 100
- cortical microinfarcts, 20
- C-reactive protein (CRP), 196
- cystatin C-related cerebral amyloid angiopathy, 86
- Dejerine's syndrome, 223–224
- Dejerine-Roussy syndrome, 221
- dementia, 25–26, *See also* Alzheimer's disease; cognitive function; vascular dementia (VaD)  
 blood-brain barrier permeability relationship, 57–58  
 cerebral blood flow studies, 184  
 diabetes association, 239  
 lacune impact, 237  
 MRI role in assessment, 299–300  
 stroke association, 239  
 white matter pathology relationships, 236–237
- depression, 263–265
- post-stroke (PSD), 263  
 prevalence in the elderly, 263  
 vascular, 264–265  
 treatment implications, 264–265
- diabetes  
 animal models, 45–46  
 common soil hypothesis, 93–95  
 dementia association, 239  
 lacunar infarct risk factors, 312–313  
 white matter pathology risk factors, 315
- diffusion tensor imaging (DTI), 168–172, 261, 342
- diffusion-weighted imaging (DWI), 168
- digital subtraction angiography (DSA)  
 intracerebral hemorrhage, 142
- dipyridamole, 228, 328
- disability, 273  
 cerebral microbleed prognostic significance, 278–279  
 lacunar infarct prognostic significance, 277–278  
 white matter lesion prognostic significance, 273–277
- dysarthria-clumsy hand syndrome, 222
- edema, 107
- embolic animal models, 43
- endothelial dysfunction, 94–95, 193  
 hyperhomocysteine-induced, 195  
 in CADASIL, 197–198  
 in sporadic small vessel diseases, 193–195  
 inflammation relationship, 193
- endothelial nitric oxide synthase (eNOS) gene variation, 195
- endothelial progenitor cells (EPC), 194  
 CADASIL patients, 197
- endothelium, 101–103, 192–193
- epidermal growth factor receptor (EGFR), 65  
 Notch3 mutations, 65
- European Centres of Excellence in Neurodegeneration guidance, 350–351
- executive functions, 243  
 assessment, 240–241  
 impairment, 240, 243
- exercise, gait disorder management, 257–258
- extracellular matrix (ECM), 103  
 focal ischemia effects, 106  
 adhesion receptors, 106  
 matrix antigen loss, 106  
 matrix proteases, 106
- Fabry's disease, 84–85, 292–294  
 clinical manifestations, 293–294  
 heterozygous females, 293
- imaging findings, 293  
 pathophysiology, 293–294  
 therapy, 294
- falls. *See also* balance disorders  
 impact in the elderly, 255  
 prevention, 257–258  
 white matter lesion association, 256
- familial amyloidosis – Finnish type (FAF), 70
- familial British dementia (FBD), 70, 86–88
- familial chilblain lupus, 69
- familial Danish dementia (FDD), 70, 86–88
- familial transthyretin (TTR)-related amyloidosis, 70
- fibrin deposition, 108–109
- fibrinoid necrosis, 4, 56, 348
- fibrohyalinosis, 5
- folate, 315
- Foville's syndrome, 223
- fractional anisotropy (FA), 168
- functional magnetic resonance imaging (fMRI), 159, 173–174  
 arterial spin labeling (ASL), 174–176
- functional status, 273  
 global functioning assessment, 274
- gait disorders, 251  
 classification, 251–253  
 LADIS study, 253–254  
 management, 257–258  
 pathological mechanisms, 256–257  
 small vessel disease association, 254–255
- generalized anxiety disorder (GAD), 266
- genome-wide association studies (GWAS), 89
- GLA gene mutation, 84
- glia limitans*, 99
- glial fibrillary acidic protein (GFAP), 203–204
- gliosis, reactive, 202–203
- global brain ischemia, 23
- global functioning assessment, 274
- granular osmiophilic (GOM) deposits, 44, 66
- hallucinations, 266
- HANAC (hereditary angiopathy with nephropathy, aneurysms and cramps) syndrome, 74, 85, 291–292
- head trauma, 149–150
- health, 273
- hematologic disorders, 150
- hemiparesis  
 ataxic, 221  
 pure motor, 220

## Index

- hemorrhagic transformation, 107–108  
 hemosiderin deposition, 150,  
     *See also* superficial siderosis  
     cerebral microbleeds, 34–35, 143  
 heparin, 228  
 hereditary cerebral hemorrhage with  
     amyloidosis  
     Dutch type (HCHWA-D), 70, 86,  
     159  
     Icelandic type (HCHWA-I), 70, 86  
 hereditary cerebral small vessel  
     diseases (SVDs), 64,  
     *See also specific conditions*  
     monogenic conditions, 82–83  
 hereditary endotheliopathy with  
     retinopathy, nephropathy,  
     and stroke (HERNS), 68, 85,  
     292  
     clinical manifestations, 294  
 hereditary vascular retinopathy  
     (HVR), 68, 85, 292  
 HINTS assessment, 223  
 hippocampal pathology  
     atrophy, 242, 302–303  
     cardiac arrest, 23  
 homocysteine. *See*  
     hyperhomocysteinemia  
 HTRA1, 290  
     functions, 68  
     mutations, 67–68, 84  
 hyalinosis, 5  
 hyperhomocysteinemia, 195  
     CADASIL patients, 197  
     rodent model, 44  
     white matter pathology association,  
     315  
 hyperlipidemia, white matter  
     pathology relationships, 315  
 hypertension, 57, 192, *See also* blood  
     pressure  
     animal models, 44  
     cerebral amyloid angiopathy  
     relationship, 32  
     cerebral vasoreactivity relationship,  
     175–176  
     cognitive decline relationship,  
     238–239  
     intracerebral hemorrhage  
     relationship, 317  
     lacunar infarct risk factors, 312  
     therapeutic induction, 227  
     vessel wall changes, 317  
     white matter pathology association,  
     314, 336  
 hypertensive vasculopathies, 4–8  
     arteriopathy, 31  
     microangiopathy, 157–159  
     imaging findings, 157–159  
     pathological findings, 13, 157–158  
 hypoperfusion, 23  
     models. *See* animal models  
 hypotensive stroke, 18, 23  
 hypoxia, 201–203  
 inflammation, 196–197  
     cerebral amyloid angiopathy, 12–13,  
     156–157  
     cerebrospinal fluid biomarkers,  
     204–205  
     endothelial dysfunction relationship,  
     193  
     focal ischemia effects, 103, 105–106  
 integrins, 101, 103  
     focal ischemia effects, 106–107  
 interleukin-6 (IL-6), 196  
 internal carotid arteries, 220, 347  
 intra-arterial stenting, 228–229  
 intracerebral hemorrhage (ICH),  
     29–34, 316–317  
     acute, 139  
     anticoagulation association, 33  
     cerebral amyloid angiopathy  
     association, 10–11, 31–33, 153,  
     158, 317  
     cerebral microbleed relationships,  
     36  
     chronic, 139  
     hemorrhagic transformation,  
     107–108  
     hypertensive microangiopathy  
     association, 158–159  
 imaging findings, 139–142  
     computed tomography (CT),  
     139–141  
     digital subtraction angiography  
     (DSA), 142  
     ICH stages, 141, 143  
     magnetic resonance imaging  
     (MRI), 141, 143  
     primary versus secondary  
     bleeding causes, 141  
     neuropathology, 29–31  
     primary, 139  
     risk factors, 317  
     secondary, 139  
     spontaneous, 10  
 intracranial branch atheromatous  
     disease, 7  
 intracranial hemorrhages, 29,  
     *See also* cerebral microbleeds  
     (CMB); intracerebral  
     hemorrhage (ICH);  
     subarachnoid hemorrhage  
 Kunitz protease inhibitor (KPI), 32  
 lacunar infarcts, 7, 52–53, 129, 217,  
     311–314  
 cerebral blood flow studies, 184  
 cognitive decline association, 239  
 epidemiology, 217–218  
     demographics and risk factors,  
     217  
     ethnicity, 217–218  
     percentage of acute strokes, 217  
 hypertensive microangiopathy,  
     158  
 prognostic significance, 277–278  
 risk factors, 312–314  
     community studies, 313  
     stroke studies, 312–313  
 silent lacunar infarcts, 132–136  
     differentiation from other  
     cavities, 135–136  
 terminology, 136  
 lacunar stroke, 277, 323  
     acute care, 228–229, 323–325  
     antiplatelet therapy, 227–228, 325  
     blood pressure management,  
     227  
     thrombolytic therapy, 226–227,  
     323–324  
     acute imaging, 229–230  
     atrial fibrillation and, 330  
     carotid stenosis and, 330  
     cerebral blood flow studies, 184  
     recurrence, 323  
     secondary prevention, 325–330  
     antiplatelet agents, 325–328  
     blood pressure reduction,  
     328–330  
     lipid lowering therapy, 328  
     trials, 326  
     syndromes, 220–222  
 lacunar syndrome, 129, 136  
 lacunes, 17–19, 129, 311, 348,  
     *See also* lacunar infarcts  
     as surrogate markers, 339–340  
     cerebral microangiopathy  
     relationship, 339  
     clinical outcome correlation, 339,  
     341  
     sample size calculation for trials,  
     339  
     cognitive impact, 237, 339, 341  
     incidence, 339, 341  
     research definition, 351  
 LADIS (Leukoaraiosis And DISability)  
     study, 304  
 gait disorders, 253–254  
 white matter lesion prognostic  
     significance, 274–276  
 language impairment, 242  
 lateral lenticulostriate arteries, 219  
 leptomeninges, basal ganglia, 8  
 leukoaraiosis. *See* white matter  
     pathology



## Index

- Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study, 197
- lipid lowering therapy. *See also* statin therapy  
 secondary stroke prevention, 328
- lipohyalinosis, 6, 56–57, 348
- long perforating artery occlusion, 129
- M5R<sup>-/-</sup> transgenic mouse model, 45
- magnetization transfer imaging (MTI), 342
- mania, 265–266
- Marie–Foix syndrome, 222
- mast cells, 104
- matrix metalloproteinases (MMPs), 32, 95, 196–197  
 as cerebrospinal fluid biomarkers, 204–205  
 focal ischemia effects, 106
- medial lenticulostriate arteries, 220
- medullary syndromes, 223–224
- memory impairment, 242
- metastases from malignant melanoma, 149
- methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, 195
- microaneurysms, 4–5, 348  
 rupture, 5
- microatheroma, 6, 57, 348
- microglia, 104
- microinfarcts, 12, 303–304  
 cortical, 20
- microstructural changes in brain tissue  
 as surrogate markers, 342–343  
 cerebral microangiopathy  
 relationship, 342  
 rate of progression, 342
- microvasculature. *See* cerebral microvasculature
- midbrain syndromes, 222  
 medial midbrain syndrome, 222  
 midbrain tegmentum syndrome, 222
- middle cerebral artery (MCA)  
 branches, 219  
 flow velocity measurement, 182
- migraine, 284  
 CADASIL patients, 284–286
- mild cognitive impairment (MCI), 236, 238, 242, 298
- Millard–Gubler syndrome, 223
- Mini Mental State Examination (MMSE), 239
- mixed dementia, 200, 299
- Montreal Cognitive Assessment scale (MoCA), 240
- mouse unilateral common carotid occlusion (UCCAo) model, 43
- multi-infarct dementia (MID), 16
- multimodal imaging, 177
- multiple sclerosis (MS), 122, 124
- myelin basic protein (MBP), 203
- myeloperoxidase (MPO), 105
- N*-acetylaspartate (NAA), 172
- neopterin, 197
- neurofilament (NF), 207–208  
 CSF levels as biomarkers, 208–209
- neuroimaging standards, 350–351
- neuropsychological assessment, 239–243  
 attention, slowing and motor skills, 241–242  
 executive dysfunction, 240–241  
 global cognitive measures, 239–240  
 language impairment, 242  
 memory impairment, 242  
 visuoconstructional impairment, 242–243
- neurovascular unit, 101, 105,  
*See also* blood–brain barrier (BBB); cerebral microvasculature  
 focal ischemia effects, 106–107  
 small vessel disease and, 109–111  
 vessel–neuron communication, 105, 107
- nitric oxide (NO), 183
- non-focal lesions, 20
- no-reflow phenomenon, 108–109
- normal pressure hydrocephalus (NPH), 59–60
- Notch3, 65
- NOTCH3* mutations, 44, 65, 84, 88  
 animal models, 44–45  
 pathogenicity, 65–66
- obsessive compulsive disorder (OCD), 267
- oxidative stress, 193, 195–196
- palipsychism, 225
- paraoxonase, 196
- pericytes, 103–104
- perivascular spaces, 135, 351  
 dilated, 8, 158  
 differentiation from lacunar infarcts, 135–136
- plasminogen activator inhibitor type 1 (PAI-1), 194
- PMN leukocytes, 105  
 microvessel obstruction, 108
- pontine syndromes, 222–223  
 inferior medial, 223  
 lateral, 222  
 ventral, 223  
 warning syndrome, 226
- positron emission tomography (PET), 180–181
- posterior cerebral artery (PCA), 220
- posterior choroidal artery, 220
- posterior inferior cerebellar artery, 220
- post-stroke depression (PSD), 263
- presenilin (PSEN) genes, 70  
 mutations, 71
- prion-related cerebral amyloidosis, 70
- protein C, 193
- pseudoaneurysms, 5
- psychiatric symptoms, 261,  
*See also specific psychiatric disorders*  
 CADASIL patients, 286  
 small vessel disease association, 262–263
- psychosis, 266
- pure motor hemiparesis, 220
- pure sensory stroke, 221
- Raymond’s syndrome, 223
- reactive gliosis, 202–203
- reactive oxygen species (ROS), 193, 195–196
- recent small subcortical infarcts (rSSI), 351
- recurrent artery of Heubner, 220
- retinal vasculopathy with cerebral leukodystrophy (RVCL), 68–69, 85–86, 292  
 mechanisms of disease, 69  
 molecular genetics, 68, 292
- reversible cerebral vasoconstriction syndrome (RCVS), 152
- schizophrenia, 266
- Secondary Prevention of Small Subcortical Strokes (SPS3) study, 217, 325–331
- segmental arterial disorganization, 7
- selectins, 193–194
- sensorimotor stroke, 221
- Short Physical Performance Battery (SPPB), 253
- siderosis. *See* superficial siderosis
- silent infarcts, 133, *See also* lacunar infarcts
- single photon emission computed tomography (SPECT), 181
- small vessel diseases. *See* cerebral small vessel diseases (SVDs)
- small vessels, 1, 347, *See also* cerebral microvasculature
- spontaneously hypertensive stroke prone rats (SHRSP), 44

## Index

- spontaneously hypertensive stroke  
   resistant rats (SHRSR), 54–55  
 spot sign, 140–141  
 star-weighted angiography (SWAN), 147  
 statin therapy, 343  
   cerebral microbleed association, 318  
   intracerebral hemorrhage risk and, 317  
   secondary stroke prevention, 328  
 steal phenomena, 175  
 stenting, 228–229  
 STRIVE (Standards for Reporting Vascular changes on neuroimaging), 2  
 stroke, 200. *See also* acute stroke care; lacunar stroke; *specific stroke syndromes*  
   cognitive impairment association, 239  
   hypotensive, 18, 23  
   pure sensory, 221  
   sensorimotor, 221  
 Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, 328  
 stroke unit care, 229  
 subarachnoid hemorrhage (SAH)  
   cerebral amyloid angiopathy association, 33, 155  
   focal (fSAH), 150  
   differential diagnosis, 152  
   mimics, 152  
   imaging findings, 150  
 subcortical arteriosclerotic encephalopathy. *See* Binswanger's encephalopathy  
 subcortical hemorrhage, risk factors, 317. *See also* intracerebral hemorrhage (ICH)  
 subcortical vascular dementia. *See* vascular dementia (VaD)  
 sulfatide, 203–204  
 superficial siderosis, 11, 34.  
   *See also* hemosiderin deposition  
   cerebral amyloid angiopathy association, 11, 34, 155  
   differential diagnosis, 152  
   mimics, 152  
   supratentorial, 150  
   imaging findings, 150  
   pathophysiology, 152  
 superior cerebellar artery, 220  
 supratentorial superficial siderosis.  
   *See* superficial siderosis  
 surrogate markers, 336  
   lacunes, 339–340  
   microbleeds, 340–342  
   microstructural changes in brain tissue, 342–343  
   white matter pathology, 336–339  
 susceptibility-weighted imaging (SWI), 262  
   cerebral microbleeds, 145–147  
 T2-star-weighted angiography (SWAN), 147  
 tau, 208  
   CSF levels as biomarker, 208–209  
 thalamic syndromes, 224–226  
   anterior territory infarction, 224–225  
   inferolateral territory infarction, 225–226  
   paramedian territory infarction, 225  
   posterior territory infarction, 226  
 thalamogeniculate artery, 220  
 thalamoperforator artery, 220  
 thrombolytic therapy, 226–227, 323–324  
   intracerebral hemorrhage association, 33  
 thrombomodulin, 193  
 thrombosis  
   endothelium anti-thrombotic function, 103  
   small penetrating arteries, 226  
 tight junction (TJ) complexes, 101–102  
   focal ischemia effects, 107  
 tissue factor, 193–194  
 tissue factor pathway inhibitor (TFPI), 194  
 tissue inhibitors of matrix metalloproteinases (TIMP), 205  
 tissue plasminogen activator (tPA), 194  
   acute stroke care, 323–324  
 transcranial Doppler ultrasound (TCD), 182  
 TREX1  
   functions, 68–69  
   mutations, 68, 86  
   pathological effects, 69  
 two-vessel gradual occlusion (2-VGO)  
   animal model, 43  
 type IV collagen, 73  
   functions, 75  
   mutations, 74, 94. *See also* COL4A1 mutations; COL4A2 mutations  
   modifiers of disease phenotype, 76  
   mouse models, 75  
   pathogenicity, 75–76  
   pathology, 73–74, 85  
   synthesis and structure, 74  
 ultra-high field MRI, 160  
 VADAS-cog battery, 240  
 vascular cognitive impairment (VCI), 16–17, 298–299  
   Alzheimer's disease relationship, 16  
 vascular dementia (VaD), 16.  
   *See also* dementia  
   Alzheimer pathology relationship, 200, 302–304  
   cerebral blood flow studies, 184  
   diagnosis, 298–299  
   mixed dementia, 299  
 vascular depression, 264–265  
 vascular endothelial cadherin (VE-cadherin), 102  
 vasculitis, 19  
 vasoreactivity. *See* cerebral reactivity  
 venous pathology, 59–60  
 vertebral arteries, 347  
 vertebrobasilar system, 220  
 Virchow–Robin spaces. *See* perivascular spaces  
 visuoconstructional impairment, 242–243  
 vitamin B, 343  
   vitamin B12, 315  
 vitamin C, 196  
 vitamin E, 196  
 von Willebrand factor, 193  
   CADASIL patients, 197  
 Wallenberg's syndrome, 223  
 warfarin, 33  
 Weber's syndrome, 222  
 white matter hyperintensities (WMHs), 29, 118, 172, 261, 299–300  
   Alzheimer's disease and, 184, 301–302  
   blood–brain barrier relationships, 57–58  
   cerebral blood flow relationship, 174–175, 184–187  
   research definition, 351  
   white matter pathology, 314–316, 349.  
   *See also* white matter hyperintensities (WMHs)  
   as surrogate marker, 336–339, 343  
   cerebral microangiopathy relationship, 336–337  
   clinical outcome correlation, 337, 340  
   sample size calculation for trials, 337–339, 341  
   assessment, 17  
   balance disorder association, 255–256  
   blood–brain barrier permeability relationship, 57–59  
   cerebral amyloid angiopathy (CAA), 12, 155

Index

white matter pathology (cont.) cerebrospinal fluid biomarkers, 202–204 cognitive implications, 236–237, 337, 340 dementia relationships, 236–237 falls and, 256 gait disorder association, 256–257 heritability, 88 candidate gene studies, 88 genome-wide association studies, 89 hypertension association, 336	imaging findings, 117, 126 computed tomography (CT), 118–121 magnetic resonance imaging (MRI), 118–125, 336–339 multiple sclerosis separation, 122, 124 quantitation of burden, 125–126 increased arterial pulsatility relationship, 60 ischemic origin, 53 large artery aging relationships, 93	mechanisms, 314 non-focal lesions, 20 prevalence, 236 prognostic significance, 273–277 rate of progression, 337–338 risk factors, 314–315 for progression, 315–316 venous dysfunction, 59–60  xenon, 181–182  zonula occludens (ZO), 101
--	--	--